Calmare Therapeutics Inc

Calmare Therapeutics — Investor Presentation (October 2015)

25 slides from Calmare Therapeutics's investor presentation, Oct 23, 2015

  1. Slide 1: Company Presentation October 2015

    Company Presentation October 2015 © 2015 Calmare Therapeutics Incorporated

  2. Slide 2: Safe Harbor Disclosure

    THIS PRESENTATION CONTAINS “FORWARD-LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE

  3. Slide 3: Company Overview

    Established, headquartered in Fairfield, CT since 1968 © 2015 Calmare Therapeutics Incorporated Publicly-traded in the U.S., Over-the-Counter (“CTTC”) Company Overview

  4. Slide 4: Flagship Product: The Calmare Pain Therapy Device

    The Calmare ® Pain Therapy Device neuro-modulation for the treatment of chronic, stable peripheral neuropathic pain using electro-stimulation. ▪ U.S. FDA 510(k) clearance #K081255 ▪ G.S.A. #V797P-4300B ▪ CE-mark for European sales Flagship Product © 2015 Calmare Therapeutics Incorporated

  5. Slide 5: Calmare Pain Mitigation Therapy

    Calmare Pain Mitigation Therapy™ Calmare PMT © 2015 Calmare Therapeutics Incorporated

  6. Slide 6: Medical Theory: The central nervous system responds to coded information

    The central nervous system responds to coded information. Medical Theory © 2015 Calmare Therapeutics Incorporated

  7. Slide 7: Medical Theory: In chronic pain, the pain codes are false

    Medical Theory Yet, in chronic pain, the pain codes sent are false! © 2015 Calmare Therapeutics Incorporated

  8. Slide 8: Medical Theory: Calmare PMT interferes with the neuromatrix

    Medical Theory © 2015 Calmare Therapeutics Incorporated Calmare Pain Mitigation Therapy™ interferes with this neuromatrix 1 and provides “No Pain” codes. 1 Katholi, B., Daghstani, S. S., Banez, G. A., & Brady, K. K. (2014). Noninvasive Treatments for Pediatric Complex Regional Pain Syndrome: A Focus

  9. Slide 9: Treatment Regimen

    10 to 12 consecutive 45-minute, daily sessions with an allowable 2-day break for weekends . Treatment Regimen © 2015 Calmare Therapeutics Incorporated

  10. Slide 10: Treatment Expectations

    Pain relief expected after the first treatment Accretivepain relief over 2-week treatment period First treatment drug-free pain relief lasting to 2 to 6 months Booster treatmentscan offer additional 6 months or more Treatment Expectations © 2015 Calmare Therapeutics Incorporated

  11. Slide 11: Primary Diagnoses

    1.Chemotherapy-InducedPeripheralNeuropathy(CIPN) 2.ChronicRegionalPainSyndrome(CRPS) 3.FailedBackSurgerySyndrome 4.ChronicPost-herpeticNeuralgia(Shingles) 5.SciaticandLumbarPain 6.LowBackPain(LBP) 7.Post-SurgicalPain 8.BrachialPlexusPain 9.PhantomLimbSyndrome 10.NeuropathicPain Primary Diagnoses © 2

  12. Slide 12: Million U.S. adults in chronic pain daily

    “ 116 million U.S.adultsinchronicpaindaily ~ American Academy of Pain Medicine, 2015 ~

  13. Slide 13: Deaths every day from opioid prescription painkillers

    “ 45 peopledie every day from opioid prescription painkillers –more deaths thanheroin and cocaine overdose combined ~ National Survey on Drug Use and Health. 2015~ “

  14. Slide 14: $5.1 billion global neurostimulation devices market

    “ $ 5.1 billion Global neurostimulationdevices market ~CAGR of 12.7% between 2014 and 2020 ~

  15. Slide 15: Calmare PMT Pilot Study Results

    •33 patients •Pilot study •Terminal cancer patients •Severe drug resistance •10 treatments Marineo G et al International Congress Series 1255(203) 381-388 Calmare PMT™ Pilot Study Results The pain was reduced to zero. Pilot Study © 2015 Calmare Therapeutics Incorporated

  16. Slide 16: Calmare PMT vs. Clonazepam

    (a) Clonazepam (control) versus Calmare PMT™ (b) VAS for all patients (26/drugs + 26/CT) G. Marineo, T. Smith, et al, JPSM 2011 72% of patients pain and drug free 20% of patients on reduced drug dosages Calmare PMT vs. Drugs © 2015 Calmare Therapeutics Incorporated Calmare PMT™ vs. Clonazepam

  17. Slide 17: Calmare PMT and Breast Cancer Patients (CIPN)

    64% reduction in pain score Smith T. et al Journal of Pain And Symptom Management2010 Calmare PMT and CIPN © 2015 Calmare Therapeutics Incorporated Calmare PMT™ and Breast Cancer Patients (CIPN)

  18. Slide 18: U.S. Government Contracts

    U.S. Government contractor in good-standing since 2010 • Contract #V797P-4300B • Sales to U.S. military hospitals and clinics U.S. Veterans Administration contract • Lower Back Surgery Syndrome (LBSS) • 10% pain intensity improvement U.S. Government Contracts © 2015 Calmare Therapeutics Incorporated

  19. Slide 19: Global Commercial Sales

    United States: • private practices • hospitals with specialized medical practices. Overseas: • licensed and accredited medical physicians, and hospitals • Ministry of Health departments that honor the Calmare Pain Therapy Device’s U.S. FDA 510(k) cleared status. Global Commercial Sales © 2015 Calmar

  20. Slide 20: Centers of Excellence

    Centers of Excellence © 2015 Calmare Therapeutics Incorporated Regional hubs x Calmare medical staff treat patients x CPMT licensure and training x Local presence near/on V.A. bases

  21. Slide 21: Conrad Mir, President & CEO

    Conrad Mir, Director, President & CEO –Conrad has over twenty years of investment banking, financial structuring, and corporate reengineering experience. He has served in various executive management roles and on the Board of Directors of several companies in the biotechnology industry. Most recentl

  22. Slide 22: Dr. Stephen J. D'Amato, Chief Medical Officer

    Dr. Stephen J. D’Amato, MD, FACEP, Chief Medical Officer –Dr. D’Amato has been practicing medicine in Rhode Island for 35 years. Over the past six years, he has been the foremost Calmare ® Pain Therapy Device practitioner with over 1000 patients treated in his medical practice. Prior to joining Calm

  23. Slide 23: Peter Brennan, Chairman and VADM Robert Conway, Director

    Peter Brennan, Chairman–As Chairman of the Board of Directors of CTI, Peter brings financial and governance leadership to the company. He spent the last 30 years working in the investment management business and is the founder of Damel Investments LLC which invests in small capitalized technology co

  24. Slide 24: Carl O'Connell, Director

    Carl O’Connell, Director–Carlhas been a director of our Company since January 2013, having served as President and Chief Executive Officer from November 2012 until September 2013.He has 30 years of experience in the healthcare field and 20 years as a leader in the medical device arena. Prior to that

  25. Slide 25: Thank you! Contact

    Conrad Mir President & CEO +1 973.876.1774 [email protected] www.calmaretherapeutics.com www.calmarett.com © 2015 Calmare Therapeutics Incorporated Thank you! OTC:CTTC

Calmare Therapeutics — Investor Presentation (October 2015) on 6ix